{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:13:48Z","timestamp":1788930828233,"version":"build-2803163510"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03960-1","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:02:18Z","timestamp":1768633338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies"],"prefix":"10.1007","volume":"82","author":[{"given":"Mahesh","family":"Rathod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Kadari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana Das","family":"Kadavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Jagtap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-8761","authenticated-orcid":false,"given":"Krishna","family":"Undela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"3960_CR1","doi-asserted-by":"crossref","unstructured":"Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer [Internet] 9:543\u201353. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2405803323000584","DOI":"10.1016\/j.trecan.2023.04.002"},{"key":"3960_CR2","doi-asserted-by":"crossref","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol [Internet] 40:511\u201323. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1471490619300766","DOI":"10.1016\/j.it.2019.04.002"},{"key":"3960_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/genetics\/144.1.95","volume":"144","author":"HK Salz","year":"1996","unstructured":"Salz HK, Flickinger TW (1996) Both loss-of-function and gain-of-function mutations in snf define a role for snRNP proteins in regulating Sex-lethal pre-mRNA splicing in Drosophila development. Genetics 144:95\u2013108. https:\/\/doi.org\/10.1093\/genetics\/144.1.95","journal-title":"Genetics"},{"key":"3960_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/his.14704","volume":"81","author":"S Imran","year":"2022","unstructured":"Imran S, Golden A, Feinstein M, Plodkowski A, Bodd F, Rekhtman N et al (2022) Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease. Histopathology 81:724\u2013731. https:\/\/doi.org\/10.1111\/his.14704","journal-title":"Histopathology"},{"key":"3960_CR5","doi-asserted-by":"publisher","unstructured":"Wang Y, Cui C, Deng L, Wang L, Ren X (2023) Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022. Front Immunol [Internet] 14. Available from: https:\/\/doi.org\/10.3389\/fimmu.2023.1127128","DOI":"10.3389\/fimmu.2023.1127128"},{"key":"3960_CR6","doi-asserted-by":"publisher","unstructured":"A PM, Robert S, D HM (2018) Immune-related adverse events associated with immune checkpoint blockade. New England J Med [Internet] 378:158\u201368. Available from: https:\/\/doi.org\/10.1056\/NEJMra1703481","DOI":"10.1056\/NEJMra1703481"},{"key":"3960_CR7","doi-asserted-by":"crossref","unstructured":"Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB (2018) Anti\u2013programmed cell death 1\/ligand 1 (PD-1\/PD-L1) antibodies for the treatment of urothelial carcinoma: state of the art and future development. Clin Genitourin Cancer [Internet] 16:117\u201329. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1558767317303622","DOI":"10.1016\/j.clgc.2017.11.002"},{"key":"3960_CR8","doi-asserted-by":"publisher","unstructured":"James L, Vanna C-S, Rene G, Jean-Jacques G, Piotr R, D LC et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England J Med [Internet] 381:1535\u201346. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1910836","DOI":"10.1056\/NEJMoa1910836"},{"key":"3960_CR9","doi-asserted-by":"crossref","unstructured":"Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S et al (2021) Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol [Internet] 32:917\u201325. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753421011017","DOI":"10.1016\/j.annonc.2021.03.204"},{"key":"3960_CR10","doi-asserted-by":"publisher","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK et al (217) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol [Internet] 8. Available from: https:\/\/doi.org\/10.3389\/fphar.2017.00561","DOI":"10.3389\/fphar.2017.00561"},{"key":"3960_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40264-016-0444-7","volume":"39","author":"MT Angamo","year":"2016","unstructured":"Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE (2016) Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf 39:847\u2013857. https:\/\/doi.org\/10.1007\/s40264-016-0444-7","journal-title":"Drug Saf"},{"key":"3960_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145:1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neurooncol"},{"key":"3960_CR13","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/fcp.12558","volume":"34","author":"N Anthony","year":"2020","unstructured":"Anthony N, Bourneau-martin D, Ghamrawi S, Lagarce L, Babin M, Briet M (2020) Drug-induced vitiligo: a case\/non-case study in Vigibase\u00ae, the WHO pharmacovigilance database. Fundam Clin Pharmacol 34:736\u2013742. https:\/\/doi.org\/10.1111\/fcp.12558","journal-title":"Fundam Clin Pharmacol"},{"key":"3960_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","volume":"41","author":"R Postigo","year":"2018","unstructured":"Postigo R, Brosch S, Slattery J, van Haren A, Dogn\u00e9 J-M, Kurz X et al (2018) EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf 41:665\u2013675. https:\/\/doi.org\/10.1007\/s40264-018-0647-1","journal-title":"Drug Saf"},{"key":"3960_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","volume":"14","author":"E Raschi","year":"2019","unstructured":"Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M et al (2019) Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system. Target Oncol 14:205\u2013221. https:\/\/doi.org\/10.1007\/s11523-019-00632-w","journal-title":"Target Oncol"},{"key":"3960_CR16","doi-asserted-by":"crossref","unstructured":"Arias LHM, Fadrique RS, Garc\u00eda SP, Gil MS, Lobato CT, Ortega PG (2018) Antipsychotics and cardiovascular risk: A case\/non-case study. Psychiatry Res [Internet] 270:341\u20137. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165178117321807","DOI":"10.1016\/j.psychres.2018.09.014"},{"key":"3960_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/pds.848","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B (2003) Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 12:271\u2013281. https:\/\/doi.org\/10.1002\/pds.848","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3960_CR18","unstructured":"openvigil FDA: https:\/\/ov2.h2876314.stratoserver.net\/OV2\/search\/"},{"key":"3960_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/sbz093","volume":"46","author":"J De Leon","year":"2020","unstructured":"De Leon J, Sanz EJ, De las Cuevas C (2020) Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 46:1\u20133. https:\/\/doi.org\/10.1093\/schbul\/sbz093","journal-title":"Schizophr Bull"},{"key":"3960_CR20","doi-asserted-by":"crossref","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci [Internet] 10:796\u2013803. Available from: https:\/\/www.medsci.org\/v10p0796.htm","DOI":"10.7150\/ijms.6048"},{"key":"3960_CR21","doi-asserted-by":"crossref","unstructured":"Cepaityte D, Siafis S, Papazisis G (2021) Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. Behav Brain Res [Internet] 404:113168. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0166432821000553","DOI":"10.1016\/j.bbr.2021.113168"},{"key":"3960_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S365513","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol. https:\/\/doi.org\/10.2147\/CLEP.S365513","journal-title":"Clin Epidemiol"},{"key":"3960_CR23","doi-asserted-by":"publisher","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol [Internet] 72:905\u20138. Available from: https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"3960_CR24","doi-asserted-by":"crossref","unstructured":"Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al. Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database. Int J Med Sci [Internet]. 2015;12:135\u201340. Available from: https:\/\/www.medsci.org\/v12p0135.htm","DOI":"10.7150\/ijms.10453"},{"key":"3960_CR25","doi-asserted-by":"publisher","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf [Internet] 11:3\u201310. Available from: https:\/\/doi.org\/10.1002\/pds.668","DOI":"10.1002\/pds.668"},{"key":"3960_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","volume":"21","author":"R Ma","year":"2021","unstructured":"Ma R, Wang Q, Meng D, Li K, Zhang Y (2021) Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer 21:38. https:\/\/doi.org\/10.1186\/s12885-020-07741-0","journal-title":"BMC Cancer"},{"key":"3960_CR27","doi-asserted-by":"publisher","unstructured":"Ji H, Tang X, Dong Z, Song L, Jia Y (2019) Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig [Internet] 39:319\u201330. Available from: https:\/\/doi.org\/10.1007\/s40261-018-0735-0","DOI":"10.1007\/s40261-018-0735-0"},{"key":"3960_CR28","doi-asserted-by":"publisher","unstructured":"Liu G, Zhang S, Mo Z, Huang T, Yu Q, Lu X et al (2024) Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. Front Pharmacol [Internet] 15. Available from: https:\/\/doi.org\/10.3389\/fphar.2024.1407894","DOI":"10.3389\/fphar.2024.1407894"},{"key":"3960_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00128-020-02851-8","volume":"104","author":"F Li","year":"2020","unstructured":"Li F, Zhang Y, Hao S, Xu W, Shen K, Long Z (2020) Leaching behaviour and enhanced phytoextraction of additives for cadmium-contaminated soil by Pennisetum sp. Bull Environ Contam Toxicol 104:658\u2013667. https:\/\/doi.org\/10.1007\/s00128-020-02851-8","journal-title":"Bull Environ Contam Toxicol"},{"key":"3960_CR30","doi-asserted-by":"crossref","unstructured":"Frey C, Etminan M (2024) Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies [Internet] [cited 2025 Jan 16] 59. Available from: https:\/\/www.mdpi.com\/2073-4468\/13\/3\/59","DOI":"10.3390\/antib13030059"},{"key":"3960_CR31","doi-asserted-by":"crossref","unstructured":"Rabbani SA, Khurana A, El-Tanani M, Arora MK, Sharma S, Sridhar SB, et al. Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases. Expert Opin Drug Saf. 2024;","DOI":"10.1080\/14740338.2024.2416539"},{"key":"3960_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","volume":"43","author":"X Bai","year":"2020","unstructured":"Bai X, Chen X, Wu X, Huang Y, Zhuang Y, Chen Y et al (2020) Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. J Endocrinol Invest 43:1473\u20131483. https:\/\/doi.org\/10.1007\/s40618-020-01226-4","journal-title":"J Endocrinol Invest"},{"key":"3960_CR33","doi-asserted-by":"crossref","unstructured":"Anquetil C, Salem J-E, Lebrun-Vignes B, Touhami S, Desbois A-C, Maalouf G et al (2020) Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database. J Autoimmun [Internet] 111:102454. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S089684112030069X","DOI":"10.1016\/j.jaut.2020.102454"},{"key":"3960_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","volume":"69","author":"X Bai","year":"2020","unstructured":"Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y et al (2020) Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine 69:670\u2013681. https:\/\/doi.org\/10.1007\/s12020-020-02355-9","journal-title":"Endocrine"},{"key":"3960_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1631\/jzus.B2000449","volume":"22","author":"S Huang","year":"2021","unstructured":"Huang S, Bai X, Fang T, Guo Y, Zheng K, Lin X (2021) Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO adverse drug reaction database. J Zhejiang Univ-Sci B 22:156\u2013164. https:\/\/doi.org\/10.1631\/jzus.B2000449","journal-title":"J Zhejiang Univ-Sci B"},{"key":"3960_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00408-021-00425-x","volume":"199","author":"SW Reese","year":"2021","unstructured":"Reese SW, Cone E, Marchese M, Garcia B, Chou W, Ayub A et al (2021) Lessons from pharmacovigilance: pulmonary immune-related adverse events after immune checkpoint inhibitor therapy. Lung 199:199\u2013211. https:\/\/doi.org\/10.1007\/s00408-021-00425-x","journal-title":"Lung"},{"key":"3960_CR37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/ndt\/gfab187","volume":"37","author":"L Haeuser","year":"2022","unstructured":"Haeuser L, Marchese M, Cone EB, Noldus J, Bayliss G, Kilbridge KL et al (2022) Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrol Dial Transplant 37:1310\u20131316. https:\/\/doi.org\/10.1093\/ndt\/gfab187","journal-title":"Nephrol Dial Transplant"},{"key":"3960_CR38","doi-asserted-by":"crossref","unstructured":"Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V et al (2022) Cutaneous toxicities associated with immune checkpoint inhibitors: an observational, pharmacovigilance study. J Investig Dermatol [Internet] 142:2896\u20132908.e4. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022202X2200389X","DOI":"10.1016\/j.jid.2022.04.020"},{"key":"3960_CR39","doi-asserted-by":"crossref","unstructured":"Diaz L, Jauzelon B, Dillies A-C, Le Souder C, Faillie J-L, Maria A et al (2023) Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study. J Clin Med [Internet] [cited 2025 Jan 15] 12:1985. Available from: https:\/\/www.mdpi.com\/2077-0383\/12\/5\/1985","DOI":"10.3390\/jcm12051985"},{"key":"3960_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2019.1619693","volume":"18","author":"P Aggarwal","year":"2019","unstructured":"Aggarwal P (2019) Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system. Expert Opin Drug Saf 18:623\u2013633. https:\/\/doi.org\/10.1080\/14740338.2019.1619693","journal-title":"Expert Opin Drug Saf"},{"key":"3960_CR41","doi-asserted-by":"crossref","unstructured":"Fan Q, Hu Y, Yang C, Zhao B (2019) Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. Int Immunopharmacol [Internet] 76:105866. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576919312494","DOI":"10.1016\/j.intimp.2019.105866"},{"key":"3960_CR42","doi-asserted-by":"crossref","unstructured":"Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B et al (2020) Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol [Internet] 84:106601. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576920305117","DOI":"10.1016\/j.intimp.2020.106601"},{"key":"3960_CR43","doi-asserted-by":"publisher","unstructured":"Hu F, Ye X, Zhai Y, Xu J, Guo X, Guo Z et al (2020) Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. Immunotherapy [Internet] 12:531\u201340. Available from: https:\/\/doi.org\/10.2217\/imt-2019-0120","DOI":"10.2217\/imt-2019-0120"},{"key":"3960_CR44","doi-asserted-by":"publisher","first-page":"6576","DOI":"10.1002\/cam4.3198","volume":"9","author":"G Chen","year":"2020","unstructured":"Chen G, Qin Y, Fan Q, Zhao B, Mei D, Li X (2020) Renal adverse effects following the use of different immune checkpoint inhibitor regimens: a real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med 9:6576\u20136585. https:\/\/doi.org\/10.1002\/cam4.3198","journal-title":"Cancer Med"},{"key":"3960_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11060-020-03687-2","volume":"152","author":"T Mikami","year":"2021","unstructured":"Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al (2021) Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neuro-Oncol 152:135\u2013144. https:\/\/doi.org\/10.1007\/s11060-020-03687-2","journal-title":"J Neuro-Oncol"},{"key":"3960_CR46","doi-asserted-by":"crossref","unstructured":"Chen C, Wu B, Zhang C, Xu T (2021) Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol [Internet] 95:107498. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S156757692100134X","DOI":"10.1016\/j.intimp.2021.107498"},{"key":"3960_CR47","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","volume":"149","author":"DM Filippini","year":"2021","unstructured":"Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A et al (2021) Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis. Int J Cancer 149:675\u2013683. https:\/\/doi.org\/10.1002\/ijc.33592","journal-title":"Int J Cancer"},{"key":"3960_CR48","doi-asserted-by":"publisher","unstructured":"Liu H, Li Y, Li J, Zhang Q, Wu J, Li X et al (2023) Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol [Internet] 14. Available from: https:\/\/doi.org\/10.3389\/fphar.2023.1199031","DOI":"10.3389\/fphar.2023.1199031"},{"key":"3960_CR49","doi-asserted-by":"publisher","first-page":"8754","DOI":"10.1002\/cam4.4343","volume":"10","author":"F Hu","year":"2021","unstructured":"Hu F, Zhai Y, Yuan L, Liang J, Xu J, Guo X et al (2021) Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: an observational, retrospective, pharmacovigilance study leveraging US FARES database. Cancer Med 10:8754\u20138762. https:\/\/doi.org\/10.1002\/cam4.4343","journal-title":"Cancer Med"},{"key":"3960_CR50","doi-asserted-by":"publisher","unstructured":"Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhou X et al (2022) Metabolic and nutritional disorders following the administration of immune checkpoint inhibitors: a pharmacovigilance study. Front Endocrinol (Lausanne) [Internet] 12. Available from: https:\/\/doi.org\/10.3389\/fendo.2021.809063","DOI":"10.3389\/fendo.2021.809063"},{"key":"3960_CR51","doi-asserted-by":"publisher","unstructured":"Zhang P, Lao D, Chen H, Zhao B, Du Q, Zhai Q et al (2022) Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. Front Immunol [Internet] 13. Available from: https:\/\/doi.org\/10.3389\/fimmu.2022.778635","DOI":"10.3389\/fimmu.2022.778635"},{"key":"3960_CR52","doi-asserted-by":"crossref","unstructured":"Zhu J, Wu J, Chen P, You K, Su J, Gao Z et al (2022) Acute kidney injury associated with immune checkpoint inhibitors: a pharmacovigilance study. Int Immunopharmacol [Internet] 113:109350. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576922008347","DOI":"10.1016\/j.intimp.2022.109350"},{"key":"3960_CR53","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1002\/cam4.5438","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen Y, Zeng Z, Liu A (2023) Arrhythmic events associated with immune checkpoint inhibitors therapy: a real-world study based on the Food and Drug Administration Adverse Event Reporting System database. Cancer Med 12:6637\u20136648. https:\/\/doi.org\/10.1002\/cam4.5438","journal-title":"Cancer Med"},{"key":"3960_CR54","doi-asserted-by":"crossref","unstructured":"Xia S, Gong H, Zhao Y, Guo L, Wang Y, Zhang B et al (2022) Association of pulmonary sepsis and immune checkpoint inhibitors: a pharmacovigilance study. Cancers (Basel) [Internet] [cited 2025 Jan 15] 15:240. Available from: https:\/\/www.mdpi.com\/2072-6694\/15\/1\/240","DOI":"10.3390\/cancers15010240"},{"key":"3960_CR55","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.1002\/cam4.5655","volume":"12","author":"Y Xu","year":"2023","unstructured":"Xu Y, Yan C, Zhao Y, Li D, Guo M, Cui X (2023) Hepatic failure associated with immune checkpoint inhibitors: an analysis of the Food and Drug Administration Adverse Event Reporting System database. Cancer Med 12:9167\u20139174. https:\/\/doi.org\/10.1002\/cam4.5655","journal-title":"Cancer Med"},{"key":"3960_CR56","doi-asserted-by":"publisher","unstructured":"Guo Q, Zhao JN, Liu T, Gao J, Guo H, Cheng JM (2023) Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis. Front Pharmacol [Internet] 14. Available from: https:\/\/doi.org\/10.3389\/fphar.2023.1057134","DOI":"10.3389\/fphar.2023.1057134"},{"key":"3960_CR57","doi-asserted-by":"publisher","unstructured":"Xu Z, Qi G, Liu X, Li Z, Zhang A, Ma J et al (2023) Hepatotoxicity in immune checkpoint inhibitors: a pharmacovigilance study from 2014\u20132021. Yeung S-CJ, editor. PLoS One [Internet] [cited 2025 Jan 15] 18:e0281983. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0281983","DOI":"10.1371\/journal.pone.0281983"},{"key":"3960_CR58","doi-asserted-by":"publisher","unstructured":"Xia S, Gong H, Wang Y, Liu L, Zhao Y, Guo L et al (2023) Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the FAERS database. Front Pharmacol [Internet] 14. Available from: https:\/\/doi.org\/10.3389\/fphar.2023.1129730","DOI":"10.3389\/fphar.2023.1129730"},{"key":"3960_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-023-03171-9","volume":"24","author":"P Chen","year":"2023","unstructured":"Chen P, Zhu J, Xu Y, Huang Q, Su J, Gao Z et al (2023) Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database. BMC Nephrol 24:107. https:\/\/doi.org\/10.1186\/s12882-023-03171-9","journal-title":"BMC Nephrol"},{"key":"3960_CR60","doi-asserted-by":"crossref","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T et al (2023) Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. EClinicalMedicine [Internet] 59:101967. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S258953702300144X","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"3960_CR61","doi-asserted-by":"publisher","unstructured":"Kong Q, Wang H, Ren X, Zhuo Y, Peng J (2023) Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA adverse event reporting system. Cancer Med [Internet] 12:19491\u20139. Available from: https:\/\/doi.org\/10.1002\/cam4.6559","DOI":"10.1002\/cam4.6559"},{"key":"3960_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.36401\/JIPO-22-38","volume":"6","author":"U Ebinama","year":"2023","unstructured":"Ebinama U, Sheshadri A, Anand K, Swaminathan I (2023) Pulmonary immune-related adverse events of PD-1 versus PD-L1 checkpoint inhibitors: a retrospective review of pharmacovigilance. J Immunother Precis Oncol 6:177\u2013184. https:\/\/doi.org\/10.36401\/JIPO-22-38","journal-title":"J Immunother Precis Oncol"},{"key":"3960_CR63","doi-asserted-by":"publisher","first-page":"204209862312242","DOI":"10.1177\/20420986231224227","volume":"15","author":"T Jiang","year":"2024","unstructured":"Jiang T, Su H, Xu J, Li C, Zhang N, Li Y et al (2024) Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2021. Ther Adv Drug Saf 15:20420986231224228. https:\/\/doi.org\/10.1177\/20420986231224227","journal-title":"Ther Adv Drug Saf"},{"key":"3960_CR64","doi-asserted-by":"crossref","unstructured":"Abrahao A, Ten\u00f3rio PH de M, Rodrigues M, Mello M, Nascimento OJM (2024) Guillain-Barr\u00c3\u00a9 syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data. BMJ Neurol Open [Internet] 6:e000544. Available from: https:\/\/neurologyopensite-bmj.vercel.app\/content\/6\/1\/e000544","DOI":"10.1136\/bmjno-2023-000544"},{"key":"3960_CR65","doi-asserted-by":"publisher","first-page":"e37587","DOI":"10.1097\/MD.0000000000037587","volume":"103","author":"Q Tang","year":"2024","unstructured":"Tang Q, Han Y, Song M, Peng J, Zhang M, Ren X et al (2024) The association of hypophysitis with immune checkpoint inhibitors use: gaining insight through the FDA pharmacovigilance database. Medicine (Baltimore) 103:e37587","journal-title":"Medicine (Baltimore)"},{"key":"3960_CR66","doi-asserted-by":"publisher","unstructured":"Shi H, He Y, Dan S, Yang L, Wang J, Chen L et al (2024) Endocrine system-related adverse events associated with PD-1\/PD-L1 inhibitors: data mining from the FDA adverse event reporting system. Front Med (Lausanne) [Internet] 11. Available from: https:\/\/doi.org\/10.3389\/fmed.2024.1366691","DOI":"10.3389\/fmed.2024.1366691"},{"key":"3960_CR67","doi-asserted-by":"crossref","unstructured":"Ren X, Wang H, Deng L, Wang W, Wang Y (2024) Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: a real-world pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database (2014\u20132022). Int Immunopharmacol [Internet] 136:112301. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S156757692400821X","DOI":"10.1016\/j.intimp.2024.112301"},{"key":"3960_CR68","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1186\/s12885-024-12947-7","volume":"24","author":"X Ren","year":"2024","unstructured":"Ren X, Li L, Chen Y, Cui X, Wan R, Wang Y (2024) Adverse reactions of immune checkpoint inhibitors combined with proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions. BMC Cancer 24:1193. https:\/\/doi.org\/10.1186\/s12885-024-12947-7","journal-title":"BMC Cancer"},{"key":"3960_CR69","doi-asserted-by":"publisher","first-page":"23699","DOI":"10.1038\/s41598-024-75271-x","volume":"14","author":"D Mo","year":"2024","unstructured":"Mo D, Yang X, Xu G, Zhang X, Wang K, Lei L et al (2024) Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors. Sci Rep 14:23699. https:\/\/doi.org\/10.1038\/s41598-024-75271-x","journal-title":"Sci Rep"},{"key":"3960_CR70","doi-asserted-by":"crossref","unstructured":"Milutinovic S, Jancic P, Jokic V, Petrovic M, Dumic I, Rodriguez AM et al (2024) Pembrolizumab-associated cardiotoxicity: a retrospective analysis of the FDA adverse events reporting system. Pharmaceuticals [Internet] [cited 2025 Jan 16] 17:1372. Available from: https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1372","DOI":"10.3390\/ph17101372"},{"key":"3960_CR71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11096-024-01713-1","volume":"46","author":"Y Oka","year":"2024","unstructured":"Oka Y, Matsumoto J, Takeda T, Iwata N, Niimura T, Ozaki AF et al (2024) Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. Int J Clin Pharm 46:745\u2013750","journal-title":"Int J Clin Pharm"},{"key":"3960_CR72","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/pds.5108","volume":"29","author":"S Hasegawa","year":"2020","unstructured":"Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M et al (2020) Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf 29:1279\u20131294. https:\/\/doi.org\/10.1002\/pds.5108","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3960_CR73","doi-asserted-by":"publisher","first-page":"205031212091826","DOI":"10.1177\/2050312120918264","volume":"8","author":"K Matsumoto","year":"2020","unstructured":"Matsumoto K, Nakao S, Hasegawa S, Matsui T, Shimada K, Mukai R et al (2020) Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database. SAGE Open Med 8:2050312120918264. https:\/\/doi.org\/10.1177\/2050312120918264","journal-title":"SAGE Open Med"},{"key":"3960_CR74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40261-021-01042-5","volume":"41","author":"K Ogawa","year":"2021","unstructured":"Ogawa K, Kozuka Y, Uno H, Utsumi K, Noyori O, Hosoki R (2021) Spontaneous and immune checkpoint inhibitor-induced autoimmune diseases: analysis of temporal information by using the Japanese Adverse Drug Event Report Database. Clin Drug Investig 41:615\u2013627. https:\/\/doi.org\/10.1007\/s40261-021-01042-5","journal-title":"Clin Drug Investig"},{"key":"3960_CR75","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40261-023-01246-x","volume":"43","author":"Y Kanbayashi","year":"2023","unstructured":"Kanbayashi Y, Shimizu T, Anzai M, Kawai R, Uchida M (2023) Evaluation of cardiac adverse events with nivolumab using a Japanese real-world database. Clin Drug Investig 43:177\u2013184. https:\/\/doi.org\/10.1007\/s40261-023-01246-x","journal-title":"Clin Drug Investig"},{"key":"3960_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35602-w","volume":"13","author":"Y Kanbayashi","year":"2023","unstructured":"Kanbayashi Y, Shimizu T, Kojima A, Anzai M, Kawai R, Uchida M (2023) Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan. Sci Rep 13:8819. https:\/\/doi.org\/10.1038\/s41598-023-35602-w","journal-title":"Sci Rep"},{"key":"3960_CR77","doi-asserted-by":"crossref","unstructured":"Asano H, Noguchi Y, Kimura M, Usami E, Yoshimura T (2023) Pituitary-related adverse events and onset patterns caused by immune checkpoint inhibitors: analysis using the Japanese adverse drug event report database. Medicina (B Aires) [Internet] [cited 2025 Jan 15] 59:1963. Available from: https:\/\/www.mdpi.com\/1648-9144\/59\/11\/1963","DOI":"10.3390\/medicina59111963"},{"key":"3960_CR78","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1248\/bpb.b24-00130","volume":"47","author":"K Koga","year":"2024","unstructured":"Koga K, Tasaka Y, Nawa H (2024) Cross-cancer type evaluation of potential interstitial lung disease complications of immune checkpoint inhibitors using JADER. Biol Pharm Bull 47:1296\u20131300","journal-title":"Biol Pharm Bull"},{"key":"3960_CR79","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.31557\/APJCP.2024.25.7.2291","volume":"25","author":"T Koshiishi","year":"2024","unstructured":"Koshiishi T, Nishioka N, Yoshimoto K (2024) Immune-related adverse events due to concomitant use of immune checkpoint inhibitors and Chinese herbal medicines: a study based on a Japanese adverse event database. Asian Pac J Cancer Prev 25:2291","journal-title":"Asian Pac J Cancer Prev"},{"key":"3960_CR80","doi-asserted-by":"crossref","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev [Internet] 44:51\u201360. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0305737216000165","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"3960_CR81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bcp.14413","volume":"87","author":"PM Cutroneo","year":"2021","unstructured":"Cutroneo PM, Isgr\u00f2 V, Ientile V, Santarpia M, Ferlazzo G, Fontana A et al (2021) Safety profile of immune checkpoint inhibitors: an analysis of the Italian spontaneous reporting system database. Br J Clin Pharmacol 87:527\u2013541. https:\/\/doi.org\/10.1111\/bcp.14413","journal-title":"Br J Clin Pharmacol"},{"key":"3960_CR82","doi-asserted-by":"crossref","unstructured":"Li H, Sun X, Sun D, Zhao J, Xu Z, Zhao P et al (2021) Thromboembolic events associated with immune checkpoint inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. Int Immunopharmacol [Internet] 98:107818. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1567576921004549","DOI":"10.1016\/j.intimp.2021.107818"},{"key":"3960_CR83","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/ndt\/gfab187","volume":"37","author":"L Haeuser","year":"2022","unstructured":"Haeuser L, Marchese M, Cone EB, Noldus J, Bayliss G, Kilbridge KL et al (2022) Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrol Dial Transplant 37:1310\u20131316","journal-title":"Nephrol Dial Transplant"},{"key":"3960_CR84","doi-asserted-by":"publisher","unstructured":"Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N et al (2022) Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database. Front Pharmacol [Internet] 13. Available from: https:\/\/doi.org\/10.3389\/fphar.2022.803706","DOI":"10.3389\/fphar.2022.803706"},{"key":"3960_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5582\/ddt.2023.01092","volume":"18","author":"S Chen","year":"2024","unstructured":"Chen S, Ouyang L, Li L, Xiao Y, Wang S (2024) PD-1\/PD-L1 inhibitors associated hypophysitis: an analysis from the FAERS database and case reports. Drug Discov Ther 18:34\u201343","journal-title":"Drug Discov Ther"},{"key":"3960_CR86","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.4103\/jfmpc.jfmpc_1438_23","volume":"13","author":"A Tauseef","year":"2024","unstructured":"Tauseef A, Zafar M, Siddiqui SAH, Dufani J, DeVrieze B, Mirza M et al (2024) Management of immune check-point inhibitor-associated colitis in patients with advanced metastatic cancers: a review article. J Family Med Prim Care 13:2562\u20132567","journal-title":"J Family Med Prim Care"},{"key":"3960_CR87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00408-021-00425-x","volume":"199","author":"SW Reese","year":"2021","unstructured":"Reese SW, Cone E, Marchese M, Garcia B, Chou W, Ayub A et al (2021) Lessons from pharmacovigilance: pulmonary immune-related adverse events after immune checkpoint inhibitor therapy. Lung 199:199\u2013211","journal-title":"Lung"},{"key":"3960_CR88","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","volume":"110","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN (2022) Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system. Int Immunopharmacol 110:109015","journal-title":"Int Immunopharmacol"},{"key":"3960_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111606","author":"DC Moore","year":"2024","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN (2024) PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/j.intimp.2024.111606","journal-title":"Int Immunopharmacol"},{"key":"3960_CR90","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jcpt.13707","volume":"47","author":"F Wang","year":"2022","unstructured":"Wang F, Wu X (2022) Cardiovascular toxicities associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. J Clin Pharm Ther 47:1576\u20131584","journal-title":"J Clin Pharm Ther"},{"key":"3960_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2385489","author":"X Xi","year":"2024","unstructured":"Xi X, Yan X, Chen Y, Li W, Dong J, Ou X et al (2024) Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2385489","journal-title":"Expert Opin Drug Saf"},{"key":"3960_CR92","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/cpt.2615","volume":"112","author":"M Allouchery","year":"2022","unstructured":"Allouchery M, Beuvon C, P\u00e9rault-Pochat MC, Roblot P, Puyade M, Martin M (2022) Immune checkpoint inhibitors and venous thromboembolism: an analysis of the WHO pharmacovigilance database. Clin Pharmacol Ther 112:164\u2013170","journal-title":"Clin Pharmacol Ther"},{"key":"3960_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102454","author":"C Anquetil","year":"2020","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, Touhami S, Desbois AC, Maalouf G et al (2020) Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database. J Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2020.102454","journal-title":"J Autoimmun"},{"key":"3960_CR94","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s43441-021-00365-x","volume":"56","author":"Y Chisaki","year":"2022","unstructured":"Chisaki Y, Hata H, Matsumura C, Yano Y (2022) The occurrence of encephalitis due to immune checkpoint inhibitors: a pharmacovigilance study. Ther Innov Regul Sci 56:323\u2013332","journal-title":"Ther Innov Regul Sci"},{"key":"3960_CR95","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/joim.13641","volume":"294","author":"J Wong So","year":"2023","unstructured":"Wong So J, Bouibede F, Jonville-B\u00e9ra AP, Maillot F, Barbier F, Largeau B (2023) Immune checkpoint inhibitor\u2013associated capillary leak syndrome: a systematic review and a worldwide pharmacovigilance study. J Intern Med 294:58\u201368","journal-title":"J Intern Med"},{"key":"3960_CR96","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/phar.2035","volume":"37","author":"AK Ali","year":"2017","unstructured":"Ali AK, Watson DE (2017) Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy 37:1383\u20131390. https:\/\/doi.org\/10.1002\/phar.2035","journal-title":"Pharmacotherapy"},{"key":"3960_CR97","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","volume":"15","author":"JJ Jennings","year":"2019","unstructured":"Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH (2019) Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol 15:231\u2013244. https:\/\/doi.org\/10.1080\/17425255.2019.1574744","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3960_CR98","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S218756","author":"Q Durrechou","year":"2020","unstructured":"Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A et al (2020) Management of immune checkpoint inhibitor toxicities. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S218756","journal-title":"Cancer Manag Res"},{"key":"3960_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01384-0","author":"C Ma","year":"2023","unstructured":"Ma C, Meng K, Shi S, Zhao T, Chen S, Zhou X et al (2023) Clinical significance of interleukin-6, total bilirubin, CD3 + CD4 + T cells counts in the acute exacerbation of connective tissue disease-associated interstitial lung disease: a cross-sectional study. Eur J Med Res. https:\/\/doi.org\/10.1186\/s40001-023-01384-0","journal-title":"Eur J Med Res"},{"key":"3960_CR100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/imt-2021-0275","volume":"14","author":"A K\u00fc\u00e7\u00fckarda","year":"2022","unstructured":"K\u00fc\u00e7\u00fckarda A, G\u00f6kmen \u0130, \u00d6zcan E, Peker P, Akg\u00fcl F, \u00c7i\u00e7in \u0130 (2022) Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma. Immunotherapy 14:395\u2013399. https:\/\/doi.org\/10.2217\/imt-2021-0275","journal-title":"Immunotherapy"},{"key":"3960_CR101","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"3960_CR102","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/tau-21-1015","volume":"11","author":"K Ning","year":"2022","unstructured":"Ning K, Wu Z, Zou X, Liu H, Wu Y, Xiong L et al (2022) Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy. Transl Androl Urol 11:386","journal-title":"Transl Androl Urol"},{"key":"3960_CR103","doi-asserted-by":"crossref","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol [Internet] 28:368\u201376. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753419321933","DOI":"10.1093\/annonc\/mdw443"},{"key":"3960_CR104","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"3960_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, Chen EM, Wallach JD, Ross JS (2022) Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008\u201319: cross sectional study. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-071752","journal-title":"BMJ"},{"key":"3960_CR106","doi-asserted-by":"crossref","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E (2022) Transparency and robustness of safety signals. BMJ 379","DOI":"10.1136\/bmj.o2588"},{"key":"3960_CR107","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jclinepi.2021.07.014","volume":"139","author":"C Khouri","year":"2021","unstructured":"Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F et al (2021) A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol 139:191\u2013198","journal-title":"J Clin Epidemiol"},{"key":"3960_CR108","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0140-6736(13)62228-X","volume":"383","author":"P Glasziou","year":"2014","unstructured":"Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S et al (2014) Reducing waste from incomplete or unusable reports of biomedical research. Lancet 383:267\u2013276","journal-title":"Lancet"},{"key":"3960_CR109","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","volume":"374","author":"I Chalmers","year":"2009","unstructured":"Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86\u201389","journal-title":"Lancet"},{"key":"3960_CR110","doi-asserted-by":"crossref","unstructured":"Undela K, Thomas C (2025) Disproportionality methods for signal detection in pharmacovigilance. In: Signal analysis in pharmacovigilance. CRC Press, pp 124\u201334","DOI":"10.1201\/9781032629940-8"},{"key":"3960_CR111","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528110-00002","author":"J Almenoff","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R et al (2005) Perspectives on the use of data mining in pharmacovigilance. Drug Saf. https:\/\/doi.org\/10.2165\/00002018-200528110-00002","journal-title":"Drug Saf"},{"key":"3960_CR112","doi-asserted-by":"crossref","unstructured":"Tyagi S, Kumar A (2024) Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysis. Crit Rev Oncol Hematol. Elsevier Ireland Ltd","DOI":"10.1016\/j.critrevonc.2024.104398"},{"key":"3960_CR113","doi-asserted-by":"publisher","first-page":"1309540","DOI":"10.3389\/fphar.2024.1309540","volume":"15","author":"C Zhang","year":"2024","unstructured":"Zhang C, Li F, Dai Y, Zeng Y, Yu X, Shi D (2024) Risk of immune system and skin and subcutaneous tissue related adverse events associated with oxaliplatin combined with immune checkpoint inhibitors: a pharmacovigilance study. Front Pharmacol 15:1309540","journal-title":"Front Pharmacol"},{"key":"3960_CR114","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Jiang H, Xue L, Zhou M, Zhao X, Liu F et al (2024) Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system. Int J Clin Pharm 46:480\u2013487","journal-title":"Int J Clin Pharm"},{"key":"3960_CR115","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M et al (2021) Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in Eudravigilance. Drug Saf 44:957\u2013971. https:\/\/doi.org\/10.1007\/s40264-021-01086-8","journal-title":"Drug Saf"},{"key":"3960_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35155","author":"N Okada","year":"2024","unstructured":"Okada N, Yanagi T, Sasaki T, Tamura M, Ozaki M, Saisyo A et al (2024) Association between immune checkpoint inhibitor and cytomegalovirus infection: a pharmacovigilance study based on the adverse event reporting system. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.35155","journal-title":"Int J Cancer"},{"key":"3960_CR117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.clinthera.2023.01.001","volume":"45","author":"H Wang","year":"2023","unstructured":"Wang H, Yang H, Zhou X, Zhang X (2023) Hepatotoxicity associated with immune checkpoint inhibitors in clinical practice: a study leveraging data from the US Food and Drug Administration\u2019s adverse event reporting system. Clin Ther 45:151\u2013159","journal-title":"Clin Ther"},{"key":"3960_CR118","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14740338.2024.2327504","volume":"23","author":"M Chen","year":"2024","unstructured":"Chen M, He Z, Zhu J, Yang S, Gao S, Wu J et al (2024) Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database. Expert Opin Drug Saf 23:497\u2013511","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"3960_CR119","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/pds.5493","volume":"31","author":"S Gao","year":"2022","unstructured":"Gao S, He Z, Zhu J, Liang D, Zhao W, Yang S et al (2022) Ileus in patients treated with immune checkpoint inhibitors: a retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database. Pharmacoepidemiol Drug Saf 31(11):1199\u20131205","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3960_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175561","author":"C Cui","year":"2023","unstructured":"Cui C, Zhang S, Ren X, Cui W, Wang Y (2023) Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: a real-world study from 2014 to 2022 based on FAERS databases. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175561","journal-title":"Eur J Pharmacol"},{"key":"3960_CR121","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.21873\/anticanres.15844","volume":"42","author":"J Sato","year":"2022","unstructured":"Sato J, Nakano K, Shimizu T, Uchida M (2022) Evaluation of durvalumab-induced lung toxicity using a spontaneous reporting database. Anticancer Res 42:3575\u20133582","journal-title":"Anticancer Res"},{"key":"3960_CR122","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/jcph.2187","volume":"63","author":"T Niimura","year":"2023","unstructured":"Niimura T, Zamami Y, Miyata K, Mikami T, Asada M, Fukushima K et al (2023) Characterization of immune checkpoint inhibitor-induced myasthenia gravis using the US Food and Drug Administration Adverse Event Reporting System. J Clin Pharmacol 63:473\u2013479","journal-title":"J Clin Pharmacol"},{"key":"3960_CR123","doi-asserted-by":"publisher","unstructured":"Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q et al (2021) pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) Database. Front Pharmacol [Internet] 12. Available from: https:\/\/doi.org\/10.3389\/fphar.2021.663088","DOI":"10.3389\/fphar.2021.663088"},{"key":"3960_CR124","doi-asserted-by":"publisher","first-page":"109490","DOI":"10.1016\/j.intimp.2022.109490","volume":"114","author":"Q Guo","year":"2023","unstructured":"Guo Q, Gao J, Guo H, Xie J, Cheng J (2023) Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis. Int Immunopharmacol. 114:109490","journal-title":"Int Immunopharmacol."},{"key":"3960_CR125","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2023.2251381","volume":"23","author":"C Li","year":"2024","unstructured":"Li C, Li Z, Sun Q, Xiang Y, Liu A (2024) Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system. Expert Opin Drug Saf 23:777\u2013784","journal-title":"Expert Opin Drug Saf"},{"key":"3960_CR126","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/15569527.2023.2208661","volume":"42","author":"Q Fan","year":"2023","unstructured":"Fan Q, Chen H, Hu Y, Zhao B (2023) Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database. Cutan Ocul Toxicol 42:68\u201373","journal-title":"Cutan Ocul Toxicol"},{"key":"3960_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"3960_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824511","author":"R Ruggiero","year":"2022","unstructured":"Ruggiero R, Stelitano B, Fraenza F, di Mauro G, Scavone C, Sportiello L et al (2022) Neurological manifestations related to immune checkpoint inhibitors: reverse translational research by using the European real-world safety data. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.824511","journal-title":"Front Oncol"},{"key":"3960_CR129","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03960-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03960-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03960-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:06:14Z","timestamp":1771859174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03960-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3960"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03960-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate: Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Declarations"}},{"value":"The authors declare no competing interests.\u00a0Funding:\u00a0No funding was received for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}